USA, UK, Ireland Scientists Partner with Andhra Pradesh MedTech Zone (AMTZ)

IMT News Desk
IMT News Desk
· 3 min read
scientists
Dr. Jitendar Sharma, MD and CEO, AMTZ with the scientists

The Kalam Institute of Health Technology (KIHT), at the AP MedTech Zone, Visakhapatnam hosted a day long Annual review meeting of the Translational Center of Excellence in Biomaterials for Orthopedic and Dental Applications on December 22nd. This also earmarked the second meeting of the Bio-Medical Implants & Materials Mission (BIM2) Mission. Supported by the Department of Biotechnology, Govt. of India, KIHT, IISc Centre of Excellence and the Ceramic and Glass Industry Foundation, this event showcased inventions in health technology across the country which are ready for industrial uptake.

The meeting discussed healthcare innovations in Orthopedic and Dental Applications, their research, manufacturing and clinical applicability in the Indian healthcare context. Aspects of detailed intense knowledge on designs, applicability, compatibility with living systems, non-contamination attribute, antimicrobial sterilization needs etc. were also put into perspective. Annual meeting of the “Translational Centre of Excellence & Bio Implants mission” at Kalam Convention Centre – AMTZ, the Med Tech Capital of India. Curam Centre-Ireland; Georgia Tech- USA; Made Centre- South Carolina; Wyss Institute- Harvard; Tata Steel new material center; IIT Roorkee; PSG institute – Coimbatore; Sree Chitra – Trivandrum; IISc – Bangalore; CIPET- Chennai; CGCRI-Kolkata along with several industrial partners participated. To innovate biomaterials & Implants through knowledge convergence.

Stakeholders from various reputed institutions like IITs, NITs, IISc, VIT, National labs, MSME manufacturers, large scale manufacturers like Tata Steel New Materials Business, Smith & Nephew and Stryker participated in the meeting hosted at AMTZ. A host of key Medical Implant manufacturing entities also joined the event to finalize the ecosystem for academia and industry collaboration.

In his opening remarks and welcome address, Dr. Jitendar Sharma, MD and CEO, AMTZ shared the role of AMTZ and KIHT in bringing the Bio-materials community together and how the entire ecosystem can promote indigenous products researched at Indian institutions of merit.

Further, speaking on the occasion Prof. Bikramjit Basu, Professor of the Materials Research Centre, Indian Institute of Science and Principal Investigator of the Translational Centre of Excellence explained the urgent need of the hour in this discipline of science. Prof Basu is instrumental in leading the Academic Consortium of the BIM2 on a mission mode. Several Center of Excellence Mentoring Committee Members and Co-investigators presented their research and experience in the field of biomedical materials research. Industry representatives presented and participated in the discussion. The meeting concluded with a session for internal discussion and recommendations by the Mentoring Committee, which is a global committee with distinguished researchers from Ireland, USA and UK.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk